搜索
Unicycive Therapeutics Inc
UNCY添加自选
8.260USD
-0.300-3.50%
收盘 05/15, 16:00（美东）报价延迟15分钟
220.54M总市值
亏损市盈率 TTM
关于 Unicycive Therapeutics Inc 公司
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Unicycive Therapeutics Inc简介
公司代码UNCY
公司名称Unicycive Therapeutics Inc
上市日期Jun 17, 2021
CEOGupta (Shalabh)
员工数量22
证券类型Ordinary Share
年结日Jun 17
公司地址4300 El Camino Real, Suite 210
城市LOS ALTOS
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94022
电话16503840642
网址https://unicycive.com/
公司代码UNCY
上市日期Jun 17, 2021
CEOGupta (Shalabh)
Unicycive Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 5月14日 周四
更新时间: 5月14日 周四
持股股东
股东类型
持股股东
持股股东
占比
Vivo Capital, LLC
6.70%
Millennium Management LLC
4.39%
Octagon Capital Advisors LP
3.75%
Nantahala Capital Management, LLC
3.52%
Vanguard Capital Management, LLC
3.04%
其他
78.60%
持股股东
持股股东
占比
Vivo Capital, LLC
6.70%
Millennium Management LLC
4.39%
Octagon Capital Advisors LP
3.75%
Nantahala Capital Management, LLC
3.52%
Vanguard Capital Management, LLC
3.04%
其他
78.60%
股东类型
持股股东
占比
Hedge Fund
16.98%
Venture Capital
8.61%
Investment Advisor
4.70%
Individual Investor
2.36%
Investment Advisor/Hedge Fund
1.76%
Research Firm
0.54%
Pension Fund
0.29%
其他
64.76%
机构持股
更新时间: 4月1日 周三
更新时间: 4月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2026Q1
75
9.56M
35.81%
+450.87K
2025Q4
65
6.67M
31.03%
-253.32K
2025Q3
61
5.54M
31.38%
-1.91M
2025Q2
62
6.96M
54.51%
-655.75K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Vivo Capital, LLC
1.79M
7.09%
--
--
Dec 31, 2025
Millennium Management LLC
1.17M
4.65%
+157.82K
+15.55%
Jan 16, 2026
Octagon Capital Advisors LP
1.00M
3.96%
--
--
Dec 31, 2025
Nantahala Capital Management, LLC
939.20K
3.72%
--
--
Dec 31, 2025
Great Point Partners, LLC
796.56K
3.16%
--
--
Dec 31, 2025
Gupta (Shalabh K)
597.25K
2.37%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
473.56K
1.88%
--
--
Dec 31, 2025
Citadel Advisors LLC
258.30K
1.02%
+216.63K
+519.81%
Dec 31, 2025
Rosalind Advisors, Inc.
242.49K
0.96%
+242.49K
--
Apr 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
Jun 17, 2025
Merger
10→1
公告日期
除权除息日
类型
比率
Jun 17, 2025
Merger
10→1
